Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact

Clearmind Medicine Inc. announced the appointment of Mary-Elizabeth Gifford as Chief of Global Impact. Gifford will lead efforts to strengthen US partnerships, governmental and regulatory advocacy, and strategic alliances. She brings extensive experience in psychedelic policies and regulatory landscapes, having previously served as Chief of Global Impact at Psyched BioMed and led public policy at the Center for Mind-Body Medicine. Gifford’s role will focus on advancing Clearmind’s position in ethical, patient-centered psychedelic therapeutics. Clearmind is a clinical-stage biotech company focused on developing novel psychedelic-derived therapeutics to address widespread health issues, including alcohol use disorder. The company has a robust intellectual property portfolio with 31 granted patents.